

A new BCR-ABL1 *Drosophila* model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia

Roberto Bernardoni,^{1,2,5,#} Giorgia Giordani,^{1,3,4,§} Elisabetta Signorino,^{3,§} Sara Monticelli,¹ Francesca Messa,¹ Monica Pradotto,³ Valentina Rosso,³ Enrico Bracco,⁵ Angela Giangrande,⁶ Giovanni Perini,^{1,2*} Giuseppe Saglio,^{3,*} and Daniela Cilloni^{3,*#}

¹Department of Pharmacy and Biotechnology (FABIT), University of Bologna, Italy; ²Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy; ³Department of Clinical and Biological Sciences, University of Turin, Italy; ⁴Present address: Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, UK; ⁵Department of Oncology, University of Turin, Italy and ⁶Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP 67404 Illkirch, France

[§]These authors share first authorship.

^{*}These authors share last authorship.

ABSTRACT

The oncoprotein BCR-ABL1 triggers chronic myeloid leukemia. It is clear that the disease relies on constitutive BCR-ABL1 kinase activity, but not all the interactors and regulators of the oncoprotein are known. We describe and validate a *Drosophila* leukemia model based on inducible human BCR-ABL1 expression controlled by tissue-specific promoters. The model was conceived to be a versatile tool for performing genetic screens. BCR-ABL1 expression in the developing eye interferes with ommatidia differentiation and expression in the hematopoietic precursors increases the number of circulating blood cells. We show that BCR-ABL1 interferes with the pathway of endogenous *dAbl* with which it shares the target protein Ena. Loss of function of *ena* or *Dab*, an upstream regulator of *dAbl*, respectively suppresses or enhances both the BCR-ABL1-dependent phenotypes. Importantly, in patients with leukemia decreased human Dab1 and Dab2 expression correlates with more severe disease and Dab1 expression reduces the proliferation of leukemia cells. Globally, these observations validate our *Drosophila* model, which promises to be an excellent system for performing unbiased genetic screens aimed at identifying new BCR-ABL1 interactors and regulators in order to better elucidate the mechanism of leukemia onset and progression.

Introduction

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder associated with a reciprocal translocation between chromosomes 9 and 22. This process leads to the fusion of the *Abelson* (*ABL1*) tyrosine kinase gene with the *breakpoint cluster region* (*BCR*) sequences generating a fusion gene encoding the constitutively active protein tyrosine kinase BCR-ABL1. Due to its high frequency in CML patients (95%), the translocation is considered the cytogenetic hallmark of this disease.^{1,2} Although BCR-ABL1 is one of the most studied oncogenic proteins, some molecular mechanisms leading to cellular transformation are still partially unknown. In particular, positive or negative regulators of BCR-ABL1 have not been completely identified. The fruitfly, *Drosophila melanogaster*, represents a powerful tool for genome-wide genetic analysis and screens, given the functional conservation and sequence homology between human and *Drosophila* genes. Genome-wide approaches may allow identification of genetic pathways that contribute to disease onset and/or progression without *a priori* knowledge of the gene function.³ The high degree of conservation between human and



Haematologica 2019
Volume 104(4):717-728

Correspondence:

DANIELA CILLONI
daniela.cilloni@unito.it

ROBERTO BERNARDONI
roberto.bernardoni@unibo.it

Received: May 21, 2018.

Accepted: November 8, 2018.

Pre-published: November 8, 2018.

doi:10.3324/haematol.2018.198267

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/4/717

©2019 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.
Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:
<https://creativecommons.org/licenses/by-nc/4.0/legalcode>, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



Drosophila Abl (dAbl) proteins and the existence of *Drosophila* homologs for many proteins that interact functionally with BCR-ABL1 in mammals strongly support the idea that dAbl and presumably BCR-ABL1 signal transduction pathways could be highly conserved from fly to human. The *dAbl* gene is expressed at high levels in differentiating neurons and plays an important role in central nervous system, eye and epithelia development, mainly regulating cytoskeleton remodeling.⁴⁻⁶ Interestingly, Forgerty and colleagues demonstrated that the neural expression of a chimeric BCR-ABL protein carrying the human BCR fused to dAbl is able to rescue the *dAbl* mutant phenotype, suggesting that the chimeric BCR-ABL protein can effectively compensate for lack of dAbl.⁷ To further identify genes and pathways involved in the onset and progression of CML, we developed and validated a genetic model based on transgenic flies that drive inducible human BCR-ABL1 expression under the control of tissue- and stage-specific promoters, providing both an excellent and powerful model to identify novel functional interactors.

Methods

Generation of BCR-ABL1 transgenic flies

The BCR-ABL1 coding sequence was amplified by polymerase chain reactions and cloned into the P-element expression vector pKS69. BCR-ABL1 kinase-dead (BCR-ABL1^{KD}) was obtained through site-directed mutagenesis (*Online Supplementary Data*). Plasmids were prepared using Qiafilter™ Plasmid Maxi Kit (Qiagen, Venlo, the Netherlands) and injected in *Drosophila* embryos (The BestGene, Inc, Chino Hills, CA, USA).

Drosophila stocks

Fly stocks were obtained from Bloomington *Drosophila* Stock Center (Department of Biology, Indiana University, Bloomington, IN, USA). RNA interference (RNAi) lines were obtained from the Vienna *Drosophila* RNAi Center (Vienna, Austria). *domelessGal4* and *STAT^{DN}* flies were kindly provided by A. Giangrande (IGBMC, Illkirch, France) (*Online Supplementary Data*).

Immunoblotting

Adult heads were dissected and homogenized in a protein extraction buffer. For cell lines, 10⁷ cells were lysed in RIPA buffer. The following primary antibodies were used: c-Abl (sc-23), Dab1 (sc-271136), p-Tyr (sc-7020), GAPDH (sc-137179) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), α -tubulin (CP06; Oncogene Research Products, Merck KGaA, Darmstadt, Germany) mouse monoclonal antibodies, BCR (sc-20707) rabbit polyclonal antibody (Santa Cruz Biotechnology) and mouse 5G2 anti-Enabled supernatant (Developmental Studies Hybridoma Bank - DSHB, University of Iowa, IA, USA). For immunoprecipitation, 1 mg of total protein extract was incubated with anti-Enabled supernatant and subsequently with protein A sepharose (Amersham Bioscience, GE Healthcare, Waukesha, WI, USA) (*Online Supplementary Data*).

Fluorescent Immunolabeling

Fly eye primordium

Eye imaginal discs were dissected from third instar larvae, fixed in 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, labeled with the rat anti-Elav 7E8A10 supernatant

(DSHB), incubated with a Cy3-conjugated anti-rat secondary antibody (Jackson ImmunoResearch, Newmarket, UK) and exposed to HOECHST (Sigma-Aldrich Corp., St. Louis, MO, USA) before mounting in Fluormount-G (Electron Microscopy Sciences, Hatfield, PA, USA) (*Online Supplementary Data*).

Primary cells

The protocol was approved by the local ethics committee (approval n. 212/2015). White blood cells (10⁵) were obtained from peripheral blood. Immunofluorescence was performed as previously described⁸. Mouse anti-Dab1 and anti-Dab2 primary antibodies (sc-271136 and sc-136963, Santa Cruz Biotechnology) and anti-mouse Alexa Fluor 568 secondary antibody (Molecular Probes-Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) were used (*Online Supplementary Data*).

Genetic analysis

Eye

Flies carrying *gmrGal4* or *sevGal4* driver constructs were crossed to the UAS-BCR-ABL1 transgenic lines. To analyze the phenotype, flies from a recombinant line carrying both *gmrGal4* and UAS-BCR-ABL1 on the third chromosome (*gmrGal4,UAS-BCR-ABL1 4M/TM3*) were crossed to lines carrying single gene mutations, deficiencies or RNAi constructs. Fifteen to 30 F1 flies from three independent crosses were classified into three phenotypic classes described in the Results section.

Melanotic nodules

domelessGal4-driven BCR-ABL1 expression was controlled with the TARGET system^{9,10} (*Online Supplementary Data*). We performed conditional expression in the medullary zone of the lymph gland starting at different stages during larvae development by moving the animals from 18°C to 29°C. Analysis of the melanotic nodule phenotype and temperature shift experiments were performed as previously described.¹¹

RNA extraction and quantitative analysis

RNA was extracted using standard procedures. Expression levels of *Dab1* and *Dab2* were evaluated by real-time polymerase chain reaction using specific on-demand kits (Hs00245445_m1 for *ABL1*, Hs00221518_m1 for *Dab1*, Hs00184598_m1 for *Dab2*, Applied Biosystems, ThermoFisher Scientific) according to published methods.¹²

Results

Expression of human BCR-ABL1 affects eye cell differentiation

The aim of this work was to set up a CML *Drosophila* model based on the expression of a completely human BCR-ABL1 fusion protein. Available *Drosophila* genetic tools allow expression of proteins of interest in developing eye cells, often inducing viable and visible phenotypic traits that can be used as a bait in genetic screening. The *Drosophila* eye differentiates during the third instar larva (L3) from the eye imaginal disc, a monolayer epithelium that is accessible to dissection. We generated several stable transgenic fly lines to express BCR-ABL1 protein using the yeast *Gal4/UAS* (*Upstream Activating Sequence*) transcriptional regulation system controlled by a gene promoter active in specific tissues and stages (*Gal4* drivers).¹⁵ BCR-ABL1 expression was first triggered with the *sevenlessGal4* (*sevGal4*) construct that drives

high levels of expression in some but not all photoreceptors,¹⁴ producing a mild rough eye similar to the one observed by Fogerty⁷ (Figure 1A-E). This suggests that BCR-ABL1 interferes with eye development as described for the human/fly chimera. To drive BCR-ABL1 expression in more eye cells, we used the *glass multimer reporterGal4* (*gmrGal4*) driver, active in all cells committed to differentiation and located posteriorly to the morphogenetic furrow,¹⁵ the cell indentation crossing the eye pri-

mordium from posterior to anterior (Figure 1N,O). BCR-ABL1 expression in these cells produced a severe “glazed” eye phenotype (Figure 1F-J, *Online Supplementary Figure S1A,B,H,I*). The regular structure of the eye was almost completely lost: ommatidia, the functional units of the eye, failed to differentiate and were no longer distinguishable. The eye was smaller, bar-shaped and misplaced extra sensory bristles appeared in the dorsal region (Figure 1H-J). Western blot




Figure 1. BCR-ABL1 expression in the developing eye cells affects photoreceptor differentiation. (A-E) Adult eyes expressing EGFP (A) or BCR-ABL1 in four independent transgenic lines, 1M (B), 3M (C), 4M (D), or 7M (E), in a subset of differentiating photoreceptor cells under the control of the *sevenlessGal4* driver construct. (C-E) High levels of BCR-ABL1 induce a “rough” eye phenotype due to impairment of cell differentiation. (F-J) Adult eyes expressing EGFP (F) or BCR-ABL1 (G-J) in all differentiating eye cells under the control of the *gmrGal4* driver construct. (H-J) BCR-ABL1 expressed at high level in all differentiating eye cells profoundly disrupts ommatidia development inducing a “glazed” phenotype, depigmented area and the appearance of extra bristles (black arrows). (K-M) Quantification of BCR-ABL1 expression (K,L) and tyrosine-phosphorylation (K,M) in protein extracts from adult heads of flies expressing either EGFP (lane 1) or BCR-ABL1 in independent transgenic fly lines (lanes 2-5). The protein extracts were probed with antibodies raised against BCR, phosphorylated tyrosine residues (p-Tyr) or α -tubulin as the loading control. (N) Schematic of the eye-antenna imaginal disc from a late third instar larva; the positions of the eye and antenna primordia and of the morphogenetic furrows are indicated. The eye imaginal disc area posterior to the morphogenetic furrow, made of cells committed to terminal differentiation, is indicated in green. The thin black square indicates the region of interest shown in panels O-T. (O,P) Eye imaginal disc from wild-type late third instar larvae expressing EGFP under the control of the *gmrGal4* driver in cells posterior to the morphogenetic furrow and expressing the pan-neuronal marker *Elav* in cells committed to terminal differentiation. (Q-T) *Elav* expression in eye imaginal discs from third instar larvae of the four independent transgenic lines that express BCR-ABL1 under the control of the *gmrGal4* driver construct. BCR-ABL1 expression reduces the number of differentiated photoreceptors as indicated by the decrease of *Elav*-expressing cells.

analysis demonstrated that the severity of the phenotype correlated with the amount and phosphorylation of BCR-ABL1 protein (Figure 1K-M): indeed the low level of BCR-ABL1 expression observed in line 1M (Figure 1K-M) resulted in a very mild phenotype (Figure 1G). To better understand the origin of the phenotype, we analyzed the expression of the pan-neuronal and eye photoreceptor marker *Elav*¹⁶ in eye imaginal discs expressing BCR-ABL1. The typical *Elav*⁺ photoreceptor clusters (Figure 1P) were reduced in number and altered in BCR-ABL1-expressing flies and this correlated with the described defects of the eye's ordered structure (Figure 1P-T). To assess whether the phenotype depends on BCR-ABL1 kinase activity, we generated transgenic flies to express a kinase-dead mutant BCR-ABL1. *gmrGal4*-driven expression of the mutant protein did not affect eye development, indicating that the BCR-ABL1 phenotype requires the enzymatic activity of the oncoprotein (Online Supplementary Figure S1A-C,H).

Expression of human BCR-ABL1 interferes with eye development by altering *dAbl* signaling

To better understand the consequences of BCR-ABL1 overexpression in the eye, we investigated whether the human oncoprotein could activate the endogenous pathway regulated by the *Drosophila* Abl kinase (*dAbl*). To quantify the phenotype we classified BCR-ABL1 eyes (line 4M) into three phenotypic classes. Class 0 represents the most frequent "glazed" phenotype. Class +1 is less severe: the eye is bigger and more prominent, and some ommatidia can be observed. Class -1 is more severe, being characterized by a less differentiated eye with evident lack of pigmentation in the most posterior region (Figure 2A). Interestingly, phenotype expressivity did not change comparing *gmrGal4,UAS-BCR-ABL1 4M* animals with *gmrGal4,UAS-BCR-ABL1 4M,UAS-EGFP* (Figure 2B, Online Supplementary Figure S1H,I) indicating that a single *gmrGal4* copy does not express a Gal4 limiting amount that could be titrated by increasing the number of UAS sequences. Since overexpression of *dAbl* (*UAS-Abl*) induces a very mild rough eye phenotype (Online Supplementary Figure S1A,B,G), we investigated whether it could enhance the BCR-ABL1 phenotype. We observed a worsening of the phenotype: all of the eyes belonged to class -1, showing smaller eyes and more evident loss of pigmentation (Figure 2B, Online Supplementary Figure S1G,H,N). We then investigated whether *dAbl* loss of function (LOF) could suppress the BCR-ABL1 phenotype. *gmrGal4,UAS-BCR-ABL1 4M* animals heterozygous for a *dAbl* hypomorphic recessive lethal allele (*Abl*^{1/+}) showed a very mild phenotypic suppression but were not statistically different from controls (Figure 2B, Online Supplementary Figure S1E,H,L). However, *dAbl* downregulation through RNAi (*Abl-RNAi*) or expression of a dominant negative kinase-defective *dAbl* (*UAS-Abl*^{K417N}) induced a significant suppression of the BCR-ABL1 phenotype (Figure 2B, Online Supplementary Figure S1D,F,H,I,K,M). Interestingly, we observed that animals expressing either *Abl-RNAi* or *UAS-Abl* or *UAS-Abl*^{K417N} showed a similar mild disorganization of the ommatidia (Online Supplementary Figure S1A,B,D,F,G) suggesting that the pathway activated by *dAbl* is indeed implicated in eye development. Furthermore, the genetic interactions between BCR-ABL1 expression and *dAbl* loss or gain of function sug-

gest that *dAbl*, *dAbl*^{K417N} and overexpressed BCR-ABL1 could compete for common binding targets. To confirm that BCR-ABL1 overexpression affects eye development by altering *dAbl* signaling cascade, we analyzed whether BCR-ABL1 could functionally interact with components of the *dAbl* pathway. In detail, we focused on four genes whose LOF mutations genetically interact with a *dAbl* mutant phenotype. Mutations of *prospero* (*pros*), a transcription factor that regulates neuronal differentiation¹⁷, *failed axon connections* (*fax*), implicated both in neurogenesis and axonogenesis¹⁸ and *Disabled* (*Dab*) that regulates cellular localization of *dAbl*¹⁹, enhance the mutant *dAbl* phenotype. Moreover, *enabled* (*ena*) gene mutations suppress a *dAbl* mutant phenotype.²⁰ Interestingly, we found that either a deletion or a mutant allele of *pros* (Figure 2C, Online Supplementary Figure S2A-C) and *fax* (Figure 2D, Online Supplementary Figure S2A,D,E) was able to enhance the BCR-ABL1 phenotype. Moreover, although the insertional *Dab*^{EY10190} allele did not change the BCR-ABL1 phenotype significantly, a deletion uncovering the *Dab* locus enhanced it (Figure 2E, Online Supplementary Figure S2A,F,G), confirming that BCR-ABL1 expression alters eye development likely by interacting with components of the *dAbl* pathway.

BCR-ABL1 expression increases phosphorylation of the *dAbl* substrate *Ena*

A genetic screen had previously identified an *ena* LOF allele as a suppressor of the recessive lethality due to *dAbl* LOF mutations.²⁰ *Ena* is a cytoskeletal regulator that facilitates actin polymerization.²¹ Its cellular localization depends on *dAbl*^{5,20,22} and it is phosphorylated by both human and *Drosophila* Abl.^{23,24} Heterozygosis of a LOF *ena* allele or of an *ena* deletion suppressed the BCR-ABL1 phenotype (Figure 2F, Online Supplementary Figure S2A,J,K). *ena* silencing with two independent constructs (*ena-RNAi*), induced a size increase and strong decrease of depigmented tissue in eyes expressing BCR-ABL1 (Figure 3A, Online Supplementary Figure S2A,L,M). Consistently, the analysis of *Elav* expression highlighted a more correct organization of photoreceptor clusters (Figure 3B-E). Furthermore, we looked at tyrosine-phosphorylation of the endogenous *Ena*. Flies expressing BCR-ABL1 showed increased levels of *Ena* tyrosine-phosphorylation (Figure 3F,H) even after *Ena* immunoprecipitation (Figure 3G,H) suggesting that *Ena* might be phosphorylated by BCR-ABL1. Taken together our data indicate that alteration of several components of the *dAbl* pathway could be important for the mechanism by which BCR-ABL1 overexpression affects eye development, likely phosphorylating conserved targets in fly eye cells.

A component of the BCR-ABL1-activated pathway in human leukemia modulates the eye phenotype in *Drosophila*

To further assess the effectiveness of the model, we investigated whether a *Drosophila* homolog of a gene known to be involved in BCR-ABL1 signaling in human leukemia was also able to modulate the BCR-ABL1 phenotype. Signal transducer and activator of transcription 5 (STAT5) is a transcription factor activated in response to cytokines and its role in malignant transformation is well established.²⁵ Several studies showed that BCR-ABL1 induces phosphorylation and constitutive activation of




Figure 2. BCR-ABL1 expression affects ommatidia development by altering the dAbl signaling pathway. (A) Adult eyes showing the phenotypic classes used to quantify the severity of the variable phenotype due to BCR-ABL1 expression in eye cells committed to terminal differentiation. Posterior is on the left. Class 0 (green) corresponds to the average phenotype shown by *gmrGal4, UAS-BCR-ABL1 4M* flies; the ommatidia are almost totally absent, the eye depigmented region is very small and the eye appears flatter than that of wild-type eyes. Class -1 (pale blue) corresponds to more severe phenotypes: the eyes are even flatter than class 0 eyes and the depigmented area is enlarged including a dorso-ventral sector in the most posterior region of the eye. Class +1 (pink) corresponds to less severe phenotypes: a few ommatidia are visible, the eyes are more bulging and the depigmented area is absent indicating better eye cell differentiation. (B-F) Adult eyes from flies of the indicated genotypes were classified to evaluate the frequency of the three phenotypic classes. (B) A piled histogram chart showing the frequencies of the different phenotypic classes in flies expressing BCR-ABL1 (*gmrGal4,4M/+*), co-expressing BCR-ABL1 and the EGFP (*UAS-EGFP/+;gmrGal4,4M/+*), expressing BCR-ABL1 but having a partial loss of the endogenous *Abl* gene through the heterozygous *Abl⁺* mutation (*Abl^{+/+};gmrGal4,4M/+*), RNAi targeting *Abl* (*Abl-RNAi/+;gmrGal4,4M/+*), expression of a dominant negative dAbl mutant (*UAS-Abl^{K417N};gmrGal4,4M/+*) or overexpression of the wild-type *Abl* protein (*UAS-Abl;gmrGal4,4M/+*). (C-F) Piled histogram charts showing the frequencies of the three phenotypic classes in flies expressing BCR-ABL1 (*gmrGal4,4M*) and heterozygous for a loss of function allele or for a deletion of genes that behave as genetic modifiers of the embryonic lethality due to *Abl* LOF: *prospero* (C), *failed axon connection* (D), *Disabled* (E) and *enabled* (F). The statistical comparisons were conducted using a Mann-Whitney test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).




Figure 3. Ena loss of function suppresses the eye phenotype due to BCR-ABL1 expression which increases phosphorylation of the dAbl target Ena. (A) Piled histogram chart showing the frequencies of the three phenotypic classes in flies co-expressing BCR-ABL1 (*gmrGal4,4M*) and EGFP (*UAS-EGFP/+;gmrGal4,4M/+*), or one of two independent *ena-RNAi* lines (VDR#43056 and VDR#106484). (B,C) Eye imaginal discs from wild-type late third instar larvae expressing EGFP under the control of the *gmrGal4* driver in cells posterior to the morphogenetic furrow (B) and expressing the pan-neuronal marker Elav in cells committed to terminal differentiation (C). (D,E) Elav expression in eye imaginal discs from late third instar larvae expressing BCR-ABL1 (D) or larvae co-expressing BCR-ABL1 and *ena-RNAi* (E) under the control of the *gmrGal4* driver construct. BCR-ABL1 expression reduces the number of differentiated photoreceptors, as indicated by a decrease of Elav-expressing cells, and *ena* downregulation suppresses this phenotypic trait. (F-H) Quantification of Ena expression and tyrosine-phosphorylation in protein extracts (F) or Ena-immunoprecipitated proteins (G) from the heads of adult flies expressing either EGFP (lane 1) or BCR-ABL1 (lane 2). Independent loads of equal amount of protein extracts or Ena-immunoprecipitated proteins were probed with antibodies raised against phosphorylated tyrosine residues (p-Tyr), Ena or α -tubulin as loading control. (H) Average signal intensity from replica of the experiment shown in (F) and (G). Ena immunoprecipitation and probing for tyrosine-phosphorylation confirmed the increase of Ena tyrosine-phosphorylation in animals expressing BCR-ABL1. The statistical comparisons in (A) were conducted using the Mann-Whitney test (* $P < 0.05$, *** $P < 0.001$).

STAT5, hindering apoptosis in leukemic cells.²⁶ The JAK/STAT pathway is required during *Drosophila* eye morphogenesis and larval hematopoiesis.^{27,28} Interestingly, loss of STAT92E function (*STAT92E⁰⁶³⁴⁶*), the fly counterpart of STAT5, induced strong suppression of the BCR-ABL1 phenotype (Figure 4, *Online Supplementary Figure S3A,B*). Flies coexpressing a STAT dominant negative allele (*STAT^{DN}*) and BCR-ABL1 showed an even weaker phenotype (Figure 4A, *Online Supplementary Figure S3A,C*) confirming that STAT is involved in the BCR-ABL1-activated pathway in the *Drosophila* eye.

The human homologs of Disabled, Dab1 and Dab2, are altered in patients with chronic myeloid leukemia

To better explore the efficacy of the model we analyzed the *Disabled* gene that encodes for an adaptor protein acting downstream of many receptor tyrosine kinases.^{17,29} In the embryo *Dab* LOF disrupts the intracellular localization of dAbl and consequently that of phosphorylated Ena and F-Actin accumulation.³⁰ In the fly eye we observed an enhancement of the BCR-ABL1 phenotype in animals heterozygous for a *Dab* deletion. Thus, we further reduced *Dab* function by gene silencing.




Figure 4. A component of the BCR-ABL1-activated pathway in human leukemia modulates the eye phenotype in Drosophila. Piled histogram chart showing the frequencies of the three phenotypic classes in flies expressing BCR-ABL1 (*gmrGal4,4M*) and heterozygous for a loss of function *STAT92E⁰⁶³⁴⁶* allele or over-expressing a dominant negative allele *STAT^{DN}*. Reduction of the function of STAT, a gene encoding the homolog of the STAT5 protein involved in the BCR-ABL1-activated pathway in human leukemia cells, suppresses the BCR-ABL1-dependent phenotype in the fly eye. The statistical comparisons were conducted using the Mann-Whitney test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

Interestingly, two independent RNAi lines worsened the BCR-ABL1 phenotype more than the *Dab* deletion did (Figures 2E and 5A, *Online Supplementary Figure S2A,F-I*): most of the eyes were smaller and showed depigmented scar-like tissue (*Online Supplementary Figure S2A,F,H,I*). Consistently, alterations of the ommatidia clusters, revealed by Elav expression, worsened compared to those of the control (Figure 5B-E). To establish whether *Dab* might have a role in CML we analyzed the two human counterparts of *Disabled*, *Dab1* and *Dab2* in human primary cells. *Dab1* is a large, common fragile site gene and the *Dab1* protein acts as a signal transducer that interacts with many receptor tyrosine kinase pathways.³¹ *Dab2* encodes for an adaptor protein implicated in growth factor signaling, endocytosis, cell adhesion, hematopoietic cell differentiation and cell signaling of various receptor tyrosine kinases.³² The expression of both genes is often decreased in many human solid cancers, suggesting their possible role in oncogenesis.^{31,33} Interestingly, quantitative real-time polymerase chain reaction analysis revealed a significant downregulation of both genes in CML patients at diagnosis compared to controls in peripheral blood or bone marrow samples (Figure 6A,G). Analysis of bone marrow samples from CML patients during molecular remission showed increased levels of expression of both *Dab1* (Figure 6B) and *Dab2* (Figure 6H) with respect to the levels in treatment-resistant patients. Moreover, immunofluorescence assays demonstrated a significant down-modulation of both proteins in peripheral blood samples at diagnosis compared to the levels in controls or patients in molecular remission (Figure 6C,D,I,J). Finally, transfection experiments in K562 cells using a plasmid carrying the whole *Dab1* coding sequence demonstrated that reactivation of *Dab1* expression reduced cell proliferation (Figure 6E,F).

BCR-ABL1 expression impairs *Drosophila* blood cell homeostasis

To further confirm the efficacy of the model, we inves-

tigated the effects of BCR-ABL1 expression in the lymph gland, the hematopoietic organ of the larva. The lymph gland begins to develop in the embryo³⁴ and grows up from multipotent progenitor cells (prohemocytes) that proliferate and enter a quiescent phase during the second instar (L2). During the third instar (L3) some prohemocytes start to proliferate again and differentiate. The lymph gland breaks apart at the beginning of metamorphosis releasing differentiated blood cells (hemocytes) into the hemolymph, the *Drosophila* blood.^{35,36} During the L3, three functional regions can be distinguished in the lymph gland:³⁷ the medullary zone, populated by prohemocytes; the posterior signaling center that regulates the exit of prohemocytes from quiescence; and the cortical zone, made up of differentiating hemocytes.^{38,39} The lymph gland can break up prematurely in late-L3 if the number of differentiating hemocyte increases. As a reaction to excessive hematopoiesis, the hemocytes aggregate and a spontaneous process of melanization takes place inducing the formation of melanotic nodules.^{11,36,40,41} Constitutive BCR-ABL1 expression under the control of the *domelessGal4* (*domeGal4*) driver, active in the medullary zone of the lymph gland,^{11,42} is lethal (*data not shown*). To overcome this problem, we repressed expression of BCR-ABL1 by co-expressing a heat-sensitive mutant of the Gal4 repressor Gal80 (*tubGal80^{TS}*) until larvae reached the desired instar (TARGET system).¹⁰ While BCR-ABL1 expression from the first instar (L1) induced lethality (*data not shown*), expression from the L2 allowed larvae to survive and to develop melanotic nodules at L3 (Figure 7A,B). This suggests that BCR-ABL1 expression in the medullary zone precursors might induce an increase of circulating hemocytes (Figure 7C). When compared to controls (Figure 7A), 45% of *domeGal4,BCR-ABL1 3M,tubGal80^{TS}* larvae showed two to three small melanotic nodules (Figure 7B,C). This correlates with an increased number of circulating hemocytes in hemolymph preparations (Figure 7D). BCR-ABL1 expression starting from the early L3 did not show




Figure 5. *Dab* downregulation enhances the eye phenotype due to BCR-ABL1. (A) Piled histogram chart showing the frequencies of the three phenotypic classes in flies co-expressing BCR-ABL1 (*gmrGal4,4M*) and EGFP (*UAS-EGFP/+;gmrGal4,4M/+*), or one of two independent *Dab-RNAi* constructs (*VDRC#13005*, *VDRC#14008*). (B,C) Eye imaginal discs from wild-type late third instar larvae expressing EGFP under the control of the *gmrGal4* driver in cells posterior to the morphogenetic furrow and expressing the pan-neuronal marker Elav in cells committed to terminal differentiation. (D,E) Elav expression in eye imaginal discs from late third instar larvae expressing BCR-ABL1 (D) or larvae co-expressing BCR-ABL1 and *Dab-RNAi* (E) under the control of the *gmrGal4* driver construct. BCR-ABL1 expression reduces the number of differentiated photoreceptors, as indicated by a decrease of Elav-expressing cells, and *Dab* downregulation enhances this phenotypic trait. The statistical comparisons were conducted using a Mann-Whitney test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

any significant phenotype (Figure 7C), indicating that only when BCR-ABL1 is expressed when prohemocytes enter quiescence is it able to increase hematopoiesis. Consistently, constitutive expression of the kinase-dead mutant *BCR-ABL1^{KD}* did not induce any significant phenotype (Figure 7C). Since *dAb1*, like *Dab* and *ena*, is expressed in the lymph gland,⁴³ we assessed whether decreased *dAb1* function is able to rescue the phenotype. We co-expressed BCR-ABL1 and *Abl-RNAi*, and observed a significant

decrease of the phenotype penetrance (Figure 7E). We then investigated whether *Dab* or *ena* downregulation interacts genetically with BCR-ABL1 expression during hematopoiesis as well. *Dab-RNAi* in the medullary zone starting from L2 was able to enhance the melanotic nodule phenotype, inducing a significant increase of the penetrance (Figure 7F). Consistently, larvae co-expressing *Dab* (*UAS-Dab*) and BCR-ABL1 in the medullary zone starting from L2 showed phenotypic suppression (Figure 7F).




Figure 6. Altered pattern of expression of the human Disabled homologs, *Dab1* and *Dab2*, in patients with chronic myeloid leukemia. (A) Downregulation of *Dab1* RNA expression in patients with chronic myeloid leukemia (CML) compared to the expression in healthy donors (CTRL). In particular we found a 1 log reduction of *Dab1* expression in both peripheral blood (PB) ($P < 0.01$) and bone marrow (BM) ($P < 0.01$) (median values $2^{-\Delta\Delta ct}$: 0.02 versus 0.3 in PB and 0.008 versus 0.04 in BM). (B) Expression pattern of *Dab1* in CML patients during molecular remission (MR) compared to that in treatment-resistant patients. (C) Immunofluorescence staining of *Dab1* protein (red) in PB samples of healthy donors, CML patients at diagnosis and CML patients during MR. Nuclei are stained in blue. (D) Quantification of *Dab1* protein expression in the immunofluorescence assay. (E) A ^3H -thymidine proliferation assay showing a 20% reduction of cell proliferation in K562 cells transfected with *Dab1* plasmid compared to control. (F) Western blot of protein extracts from K562 cells transfected with an empty vector (lane 1) and transfected with a *Dab1* expression vector (lane 2), showing detectable expression of *Dab1* only in K562 cells transfected with the *Dab1* vector. Independent loads of equal amounts of protein extract were probed with antibodies raised against BCR, *Dab1* and GAPDH as a loading control. (G) Down-regulation of *Dab2* RNA expression in CML patients compared to the expression in healthy donors. In particular *Dab2* expression was found to be statistically decreased ($P < 0.0001$ and $P < 0.0001$ in PB and BM, respectively) with median values of 0.12 versus 2.8 and 0.12 versus 0.7 in PB and BM, respectively. (H) Pattern of expression of *Dab2* in CML patients during MR compared to that in treatment-resistant patients. (I) Immunofluorescence staining of *Dab2* protein (red) in PB samples of healthy donors, CML patients at diagnosis and CML patients during MR. Nuclei are stained in blue. (J) Quantification of *Dab2* protein expression in an immunofluorescence assay. The statistical comparisons were conducted using a Student *t* test ($*P < 0.05$, $**P < 0.01$, $****P < 0.0001$). Bars indicate the standard error.

Moreover, *ena-RNAi* weakly suppressed the BCR-ABL1 phenotype (Figure 7G), decreasing the phenotype penetrance. As a control, we did not observe any phenotype due to *Dab* or *ena* downregulation or *Dab* overexpression in prohemocytes (Figure 7E,G).

Discussion

In order to identify candidate genes and pathways involved in the onset and progression of CML we developed and validated a CML genetic model based on trans-

genic *Drosophila* expressing BCR-ABL1. In order to build and characterize a human functional model that could be sensitive to pharmacological inhibition and suitable for studying the effects of BCR-ABL1 mutations identified in patients with CML, we chose to express a completely human p210-BCR-ABL1 protein, in contrast what has been done previously.⁷ The expression of the oncoprotein in all eye cells committed to differentiation as photoreceptors or accessory cells (*gmrGal4* driver) induces a strong phenotype characterized by altered differentiation of the ommatidia cells.⁴⁴ The lack of phenotype in flies expressing a BCR-ABL1 kinase-dead mutant sup-




Figure 7. BCR-ABL1 expression in the hematopoietic precursor cells of the lymph gland impairs *Drosophila* blood cell homeostasis increasing the number of circulating blood cells. (A) A *w¹¹¹⁸* mid-L3 instar larva used as the wild-type control. (B) A mid-L3 larva conditionally expressing BCR-ABL1 in the hematopoietic precursors of the lymph gland medullary zone under the control of the *domelessGal4* driver construct (*dome:GFP/+;BCR-ABL1_3M,tub80TS/+*). BCR-ABL1 expression was induced in stage L2 or early-L3 larvae by exposing the animals to 29°C during the indicated larval instars to disrupt the ability of the temperature-sensitive Gal80 mutant to inhibit Gal4 transactivation activity. The black arrows in (B) point to melanotic nodules. Anterior is on the left. (C) Penetrance of the melanotic nodule phenotype in mid-L3 control larvae expressing GFP under the control of the *domelessGal4* driver (*dome:GFP*), in larvae constitutively expressing a kinase-dead BCR-ABL1 mutant protein (*dome:GFP/+;BCR-ABL1 KD/+*) and in larvae in which BCR-ABL1 (*dome:GFP/+;BCR-ABL1_3M,tub80TS/+*) expression was induced starting from the L2 (L2) or from the early-L3 (eL3) instars. (D) Evaluation of the average number of hemocytes per field after bleeding of *dome:GFP/+;BCR-ABL1_3M,tub80TS/+* and *dome:GFP/+* larvae. BCR-ABL1 expression induces the appearance of melanotic nodules and this correlates with an increase of circulating hemocytes. (E) Penetrance of the melanotic nodule phenotype in mid-L3 control larvae (*dome:GFP*), in larvae expressing *Abi-RNAi* (*dome/Abi-RNAi*), in larvae in which BCR-ABL1 alone (*dome:GFP/+;BCR-ABL1_3M,tub80TS/+*) or together with *Abi-RNAi* (*dome/Abi-RNAi;BCR-ABL1_3M,tub80TS/+*) is expressed from the L2 instar. (F) Penetrance of the melanotic nodule phenotype in mid-L3 control larvae (*dome:GFP*), in larvae expressing *Dab-RNAi* (*dome/+;Dab-RNAi/+*), in larvae conditionally expressing the *Dab* protein (*dome:GFP/+;tub80TS/+;UAS-Dab/+*), and in larvae in which BCR-ABL1 alone (*dome:GFP/+;BCR-ABL1_3M,tub80TS/+*) or together with either *Dab-RNAi* (*dome/+;BCR-ABL1_3M,tub80TS/+;Dab-RNAi/+*) or *UAS-Dab* (*dome/+;BCR-ABL1_3M,tub80TS/+;UAS-Dab/+*) is expressed from the L2 instar. (G) Penetrance of the melanotic nodule phenotype in mid-L3 control larvae (*dome:GFP*), in larvae expressing *ena-RNAi* (*dome/+;ena-RNAi/+*), and in larvae in which BCR-ABL1 alone (*dome:GFP/+;BCR-ABL1_3M,tub80TS/+*) or together with *ena-RNAi* (*dome/+;BCR-ABL1_3M,tub80TS/+;ena-RNAi/+*) is expressed from the L2 instar. The average phenotype penetrance is calculated from three independent experiments, each involving 15-95 larvae. The statistical comparisons were conducted using a Student t test (**P*<0.05, ***P*<0.01, ****P*<0.001, ns=not significant). Bars indicate the standard error.

ports the role of kinase activity in the eye phenotype. Moreover, BCR-ABL1 expression and phosphorylation levels correlate with the severity of the phenotype. Consistently, BCR-ABL1 expression under the control of *gmrGal4* induces a decrease of photoreceptors expressing Elav in eye imaginal discs and this correlates with the disruption of the adult eye. Interestingly, partial loss of *dAbl* function also slightly reduces the number of eye cells expressing Elav at L3, and to a much greater extent at later stages of development. This suggests that *dAbl* is implicated in the maintenance of neuronal commitment^{45,46} and confirms that loss or gain of function of *dAbl*/BCR-ABL1 can alter eye cell development.⁷ We have shown that human BCR-ABL1 interacts and interferes with the *dAbl* signaling pathway. Animals expressing BCR-ABL1 and heterozygous for the recessive *Abl*^l allele or coexpressing either *Abl-RNAi* or a kinase-dead dominant negative *Abl* (*Abl*^{K417N}) showed a weaker phenotype, suggesting that BCR-ABL1 and *dAbl* proteins most likely share binding sites and/or targets of the kinase activity. Consistently, co-expression of human BCR-ABL1 and *dAbl* synergizes and the phenotype becomes more severe. Notably, *dAbl* overexpression *per se* induces a weak “rough” eye phenotype but the differentiation program is not severely disrupted. We cannot exclude that this is due to a level of *dAbl* expression below a critical threshold but it could also suggest that excessive *dAbl* might be still, at least partially, negatively regulated. This possible negative regulation seems to be overcome by BCR-ABL1 since all animals co-expressing *dAbl* and BCR-ABL1 showed a severe class -1 phenotype. Consistently, LOF or downregulation of genes known to interact genetically with *dAbl* LOF mutations interact in the same way with BCR-ABL1 expression. Namely, *pros* and *fax* alleles or deletions enhance the phenotype and this is consistent with their roles in neuronogenesis and neuronal differentiation. Moreover, *ena* LOF suppresses and *Dab* LOF enhances the *dAbl* LOF phenotype^{19,20} and we observed that both *ena* and *Dab* LOF and downregulation through RNAi also modify the BCR-ABL1 phenotype in the same way. *Ena* belongs to the ENA/VASP protein family involved in regulation of the actin cytoskeleton.^{47,48} *dAbl* regulates *Ena* by modulating its localization, most likely through its phosphorylation. It is known that both *dAbl* and the human/*Drosophila* BCR-ABL chimera phosphorylate *Ena*⁷ *in vitro* and we established that human BCR-ABL1 expression in the eye also increases *Ena* phosphorylation. This conservation of phosphorylation targets significantly increases the reliability of our model for identifying relevant BCR-ABL1 functional interactors. In this view the observation that decreased *Ena* function suppresses phenotypes due to both *dAbl* mutations²⁴ and BCR-ABL1 expression suggests that both phenotypes can be due to *Ena* mislocalization and consequently actin cytoskeleton alterations can be suppressed if *Ena* expression decreases. In *Drosophila*, *Abl* and *Dab* are often co-expressed and the phenotype due to *Dab* mutations mimics the *dAbl* phenotype. Epistasis experiments have shown that *Dab* functions upstream of both *dAbl* and *Ena*, controlling their localization and thus the actin cytoskeleton, and *Dab* LOF does indeed enhance the phenotype due to *dAbl* mutations.³⁰ Interestingly, *Dab* deletion or downregulation has the same effect on the BCR-ABL1 phenotype. These findings could be explained if *Dab* is able to regulate, at least partially, BCR-ABL1 localization. This interaction might

mitigate more severe BCR-ABL1-dependent effects when *Dab* is expressed at a physiological level but not if *Dab* is downregulated or its gene dosage is halved. Furthermore, our study showed that *Dab* human homologs are less expressed in both peripheral blood and bone marrow of CML patients at diagnosis compared to their expression in controls and are re-expressed in patients during molecular remission. Moreover, *Dab1* expression in transfected K562 cells significantly decreases cell proliferation, confirming that *Dab* activity might alleviate the pathogenic effects of BCR-ABL1. We then assessed whether our model could help to fish-out homologs of leukemia-relevant genes in an ongoing dosage-sensitive genetic screen of the whole *Drosophila* genome. To this aim we considered *STAT5*, a transcription factor phosphorylated and activated by BCR-ABL1. Interestingly, LOF conditions of *STAT92E*, encoding the fly homolog of various human *STAT*, led to suppression of the BCR-ABL1 phenotype. In order to discover a tissue that could be a reliable second read-out for identifying BCR-ABL1 interactors relevant for hematopoiesis and leukemia, we moved to the larval hematopoietic organ, the lymph gland. We conditionally expressed human BCR-ABL1 in the lymph gland medullary zone where quiescent prohemocytes reside. Only BCR-ABL1 expression during L2 induces the appearance of melanotic nodules, which correlates with an increase of circulating hemocytes. This phenotype can be suppressed by *dAbl* downregulation, confirming that *dAbl* is expressed in the lymph gland medullary zone⁴⁵ where it contributes to BCR-ABL1 pathway activation and to induction of the hematopoietic phenotype. It is worth noting that both *Dab* and *ena* interact functionally with BCR-ABL1 during hematopoiesis. In fact, while *Dab* downregulation enhances the melanotic nodule phenotype and *Dab* overexpression suppresses it, *ena* downregulation decreases the penetrance of this phenotype, confirming that *ena* and *Dab* are also expressed in the lymph gland medullary zone⁴⁵ and modulate BCR-ABL1 activity. This phenotype is visible if BCR-ABL1 is expressed from the L2, when prohemocytes become quiescent, but not if it is expressed from the early L3, when the quiescent prohemocytes are still present in the medullary zone of the lymph gland. We are tempted to speculate that the *dAbl* pathway, activated by BCR-ABL1, could be involved in the mechanisms that regulate entry of prohemocytes into the quiescent state rather than maintenance of this state. This seems consistent with the observation that the lymph glands in mid-L3 larvae expressing BCR-ABL1 from L2 are very small compared to those in controls and do not show any clear partition (Giordani and Bernardoni, *unpublished data*). This suggests that, upon BCR-ABL1 expression, most of the prohemocytes could undertake the differentiation pathway and leave the lymph gland prematurely without becoming quiescent. We did not test all pathways interacting with BCR-ABL1, for example the Tyr-receptor/Ras pathway, which is known to compete with BCR-ABL1 for binding with the Grb2/Drk proteins¹ and is likely involved in the eye phenotype since the Sevenless Tyr-receptor has an established role in eye differentiation.^{49,50} Nevertheless, we present here a new and efficient CML model based on *Drosophila* transgenic for human BCR-ABL1. This model could be a powerful tool for identifying new genes and pathways involved in the pathogenesis and progression of CML.

Acknowledgments

We thank L. Giardino, V.A. Baldassarro, C. Mangano, and L. Calzà (Fondazione IRET, Ozzano dell'Emilia-Bologna, Italy) for assistance with the confocal microscopy analysis; D. Manzoni and M. Vohattorni for excellent technical help; M. Capovilla and the Trans-FlyER, Startup Company, Ferrara, Italy for generating the BCR-ABL1 kinase-dead transgenic lines. *Drosophila* lines were

obtained from the Bloomington *Drosophila* Stock Center-BDSC (NIH P40OD018537) and primary antibodies from the Developmental Studies Hybridoma Bank (created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA, USA). We thank the Italian Association for Research on Cancer (AIRC) for funding D. Cilloni (IG10005) and G. Perini (IG11400, IG15182) and for supporting this work.

References

- Cherada B, Melo JV. Natural course and biology of CML. *Ann Hematol.* 2015;94 (Suppl 2):S107-121.
- Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. *Blood.* 2009;113(8):1619-1630.
- Gonzalez C. *Drosophila melanogaster*: a model and a tool to investigate malignancy and identify new therapeutics. *Nat Rev Cancer.* 2013;13(3):172-183.
- Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS. Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor. *Cell.* 2000;101(7):703-715.
- Grevengoed EE, Loureiro JJ, Jesse TL, Peifer M. Abelson kinase regulates epithelial morphogenesis in *Drosophila*. *J Cell Biol.* 2001;155(7):1185-1198.
- Liebl EC, Forsthoefel DJ, Franco LS, et al. Dosage-sensitive, reciprocal genetic interactions between the Abl tyrosine kinase and the putative GEF trio reveal trio's role in axon pathfinding. *Neuron.* 2000;26(1):107-118.
- Fogerty FJ, Juang JL, Petersen J, Clark MJ, Hoffmann FM, Mosher DF. Dominant effects of the bcr-abl oncogene on *Drosophila* morphogenesis. *Oncogene.* 1999;18(1):219-232.
- Cilloni D, Messa F, Arruga F, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. *Leukemia.* 2006;20(1):61-67.
- McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in *Drosophila*. *Sci STKE.* 2004;2004(220):pl6.
- McGuire SE, Roman G, Davis RL. Gene expression systems in *Drosophila*: a synthesis of time and space. *Trends Genet.* 2004;20(8):384-391.
- Giordani G, Barraco M, Giangrande A, et al. The human Smoothed inhibitor PF-04449913 induces exit from quiescence and loss of multipotent *Drosophila* hematopoietic progenitor cells. *Oncotarget.* 2016;7(34):55313-55327.
- Cilloni D, Carturan S, Bracco E, et al. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. *Leuk Res.* 2013;37(5):520-530.
- Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development.* 1993;118(2):401-415.
- Basler K, Yen D, Tomlinson A, Hafen E. Reprogramming cell fate in the developing *Drosophila* retina: transformation of R7 cells by ectopic expression of rough. *Genes Dev.* 1990;4(5):728-739.
- Freeman M. Reiterative use of the EGF receptor triggers differentiation of all cell types in the *Drosophila* eye. *Cell.* 1996;87(4):651-660.
- Robinow S, White K. The locus elav of *Drosophila melanogaster* is expressed in neurons at all developmental stages. *Dev Biol.* 1988;126(2):294-303.
- Gertler FB, Hill KK, Clark MJ, Hoffmann FM. Dosage-sensitive modifiers of *Drosophila* abl tyrosine kinase function: prospero, a regulator of axonal outgrowth, and disabled, a novel tyrosine kinase substrate. *Genes Dev.* 1993;7(3):441-453.
- Hill KK, Bedian V, Juang JL, Hoffmann FM. Genetic interactions between the *Drosophila* Abelson (Abl) tyrosine kinase and failed axon connections (fax), a novel protein in axon bundles. *Genetics.* 1995;141(2):595-606.
- Gertler FB, Bennett RL, Clark MJ, Hoffmann FM. *Drosophila* abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. *Cell.* 1989;58(1):103-113.
- Gertler FB, Doctor JS, Hoffmann FM. Genetic suppression of mutations in the *Drosophila* abl proto-oncogene homolog. *Science.* 1990;248(4957):857-860.
- Krause M, Bear JE, Loureiro JJ, Gertler FB. The Ena/VASP enigma. *J Cell Sci.* 2002;115(Pt 24):4721-4726.
- Grevengoed EE, Fox DT, Gates J, Peifer M. Balancing different types of actin polymerization at distinct sites: roles for Abelson kinase and Enabled. *J Cell Biol.* 2003;163(6):1267-1279.
- Comer AR, Ahern-Djamali SM, Juang JL, Jackson PD, Hoffmann FM. Phosphorylation of Enabled by the *Drosophila* Abelson tyrosine kinase regulates the in vivo function and protein-protein interactions of Enabled. *Mol Cell Biol.* 1998;18(1):152-160.
- Gertler FB, Comer AR, Juang JL, et al. enabled, a dosage-sensitive suppressor of mutations in the *Drosophila* Abl tyrosine kinase, encodes an Abl substrate with SH3 domain-binding properties. *Genes Dev.* 1995;9(5):521-533.
- Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. *J Exp Med.* 1999;189(8):1229-1242.
- de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. *Blood.* 1999;94(3):1108-1112.
- Bina S, Wright VM, Fisher KH, Milo M, Zeidler MP. Transcriptional targets of *Drosophila* JAK/STAT pathway signalling as effectors of haematopoietic tumour formation. *EMBO Rep.* 2010;11(3):201-207.
- Zeidler MP, Bach EA, Perrimon N. The roles of the *Drosophila* JAK/STAT pathway. *Oncogene.* 2000;19(21):2598-2606.
- Le N, Simon MA. Disabled is a putative adaptor protein that functions during signaling by the sevenless receptor tyrosine kinase. *Mol Cell Biol.* 1998;18(8):4844-4854.
- Song JK, Kannan R, Merdes G, Singh J, Mlodzik M, Giniger E. Disabled is a bona fide component of the Abl signaling network. *Development.* 2010;137(21):3719-3727.
- McAvoy S, Zhu Y, Perez DS, James CD, Smith DI. Disabled-1 is a large common fragile site gene, inactivated in multiple cancers. *Genes Chromosomes Cancer.* 2008;47(2):165-174.
- Finkielstein CV, Capelluto DG. Disabled-2: A modular scaffold protein with multifaceted functions in signaling. *Bioessays.* 2016;38 (Suppl 1):S45-55.
- Zhang Z, Chen Y, Tang J, Xie X. Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review. *Pak J Med Sci.* 2014;30(2):432-437.
- Holz A, Bossinger B, Strasser T, Janning W, Klapper R. The two origins of hemocytes in *Drosophila*. *Development.* 2003;130(20):4955-4962.
- Evans CJ, Hartenstein V, Banerjee U. Thicker than blood: conserved mechanisms in *Drosophila* and vertebrate hematopoiesis. *Dev Cell.* 2003;5(5):673-690.
- Lanot R, Zachary D, Holder F, Meister M. Postembryonic hematopoiesis in *Drosophila*. *Dev Biol.* 2001;230(2):243-257.
- Jung SH, Evans CJ, Uemura C, Banerjee U. The *Drosophila* lymph gland as a developmental model of hematopoiesis. *Development.* 2005;132(11):2521-2533.
- Krzemien J, Dubois L, Makki R, Meister M, Vincent A, Crozatier M. Control of blood cell homeostasis in *Drosophila* larvae by the posterior signalling centre. *Nature.* 2007;446(7133):325-328.
- Lebestky T, Jung SH, Banerjee U. A Serrate-expressing signaling center controls *Drosophila* hematopoiesis. *Genes Dev.* 2003;17(3):348-353.
- Luo H, Hanratty WF, Dearolf CR. An amino acid substitution in the *Drosophila* hopTum-Jak kinase causes leukemia-like hematopoietic defects. *EMBO J.* 1995;14(7):1412-1420.
- Minakhina S, Steward R. Melanotic mutants in *Drosophila*: pathways and phenotypes. *Genetics.* 2006;174(1):253-263.
- Bourbon HM, Gonzy-Treboul G, Peronnet F, et al. A P-insertion screen identifying novel X-linked essential genes in *Drosophila*. *Mech Dev.* 2002;110(1-2):71-83.
- Irving P, Uboda JM, Doucet D, et al. New insights into *Drosophila* larval haemocyte

- functions through genome-wide analysis. *Cell Microbiol.* 2005;7(3):335-350.
44. Ellis MC, O'Neill EM, Rubin GM. Expression of *Drosophila* glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. *Development.* 1993;119(3):855-865.
 45. Bennett RL, Hoffmann FM. Increased levels of the *Drosophila* Abelson tyrosine kinase in nerves and muscles: subcellular localization and mutant phenotypes imply a role in cell-cell interactions. *Development.* 1992;116(4):953-966.
 46. Xiong W, Morillo SA, Rebay I. The Abelson tyrosine kinase regulates Notch endocytosis and signaling to maintain neuronal cell fate in *Drosophila* photoreceptors. *Development.* 2013;140(1):176-184.
 47. Barzik M, Kotova TI, Higgs HN, et al. Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. *J Biol Chem.* 2005;280(31):28653-28662.
 48. Bear JE, Svitkina TM, Krause M, et al. Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. *Cell.* 2002;109(4):509-521.
 49. Olivier JP, Raabe T, Henkemeyer M, et al. A *Drosophila* SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. *Cell.* 1993;73(1):179-191.
 50. Simon MA, Dodson GS, Rubin GM. An SH3-SH2-SH3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. *Cell.* 1993;73(1):169-177.